SCHEMBL856900

SCHEMBL856900

COC(=O)c1ccc(Br)c(OC)c1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.58
POLB P06746 2/20 0.58
ALDH1A1 P00352 5/20 0.45
GAA P10253 5/20 0.45
HSD17B10 Q99714 4/20 0.45
MAPT P10636 3/20 0.45
HPGD P15428 3/20 0.45
GLA P06280 2/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
ATM Q13315 1/20 0.45
CFTR P13569 2/20 0.44
ABL1 P00519 1/20 0.44
KMT2A Q03164 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
PKM P14618 1/20 0.42
MEN1 O00255 2/20 0.42
USP2 O75604 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16108030 0.84 HSD17B10 (0.50) KDM4EPOLBALDH1A1HSD17B10MAPT
SCHEMBL25095928 0.84 KDM4E (0.49) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL31172701 0.84 KDM4E (0.46) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL30217815 0.84 KDM4E (0.49) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL1352841 0.81 GAA (0.50) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL559831 0.81 KDM4E (0.56) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL977363 0.81 KDM4E (0.44) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL857226 0.81 KDM4E (0.65) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL2472606 0.81 KDM4E (0.46) KDM4EPOLBALDH1A1GAAHSD17B10
SCHEMBL3585020 0.79 SOS1 (0.43) KDM4EPOLBALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA KDM4E 610/4885POLB 4198/4885ALDH1A1 3395/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA KDM4E 361/4885POLB 4257/4885ALDH1A1 3533/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA KDM4E 760/4885POLB 4025/4885ALDH1A1 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.